Authors
Mengchen Sun, Zitong Huang, Haibin Dong, Xingyu Lu, Shaoshuai Liu, Yajing Zhang, Lei Gong, Lin Zhong
Published in
Cellular signalling. Pages 113008. Nov 14, 2026. Epub Nov 14, 2026.
Abstract
Diabetic cardiomyopathy (DCM) is characterized by myocardial metabolic remodeling and inflammatory cell death, yet the transcriptional regulators linking metabolic stress to cardiomyocyte injury remain poorly defined.
Glutamine-rich protein 1 (QRICH1) expression was examined in hearts of mice with high-fat diet and streptozotocin-induced type 2 diabetes and in cardiomyocytes exposed to high glucose plus palmitic acid. QRICH1 transcriptional regulation of pyruvate dehydrogenase kinase 4 (PDK4) was verified by chromatin immunoprecipitation and dual-luciferase assays, and the effects of QRICH1 overexpression and PDK4 knockdown were assessed in vitro. Drug repurposing was performed by molecular docking and a drug affinity responsive target stability assay.
QRICH1 was markedly upregulated in diabetic myocardium and under glucolipotoxic conditions. QRICH1 directly bound the PDK4 promoter and transactivated its expression. QRICH1 overexpression induced caspase-1-dependent pyroptosis, impaired mitochondrial respiration, and promoted cytosolic mitochondrial DNA (mtDNA) leakage with inflammatory signaling activation, and these changes were partially reversed by PDK4 knockdown. Vericiguat showed the strongest binding affinity for QRICH1 among screened cardiovascular drugs. In DCM mice, vericiguat significantly improved cardiac function, downregulated PDK4, and restored myocardial AKT phosphorylation.
QRICH1 sustains PDK4 expression under glucolipotoxic stress, driving mitochondrial dysfunction, mtDNA release, and pyroptosis, and vericiguat represents a repurposing candidate for myocardial protection in DCM.
PMID:
43033852
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0